Jaguar Health Inc (JAGX) Stock Price, Quote & News

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infe...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 371 8300

Website: jaguar.health

Address:

200 Pine Street, Suite 400, San Francisco, United States

focafoca99 Apr. 10 at 6:07 PM

$JAGX will host an investor webcast https://www.rapidticker.com/news/jagx-reminder-jaguar-health-to-host-fe5ece

0 · Reply

Bunster Apr. 10 at 5:52 PM

$JAGX tell that to the 4 clueless pumpers

0 · Reply

andycoolbeans Apr. 10 at 5:48 PM

$JAGX billion dollar potential market ? "I am not uncertain“

1 · Reply

Omago78 Apr. 10 at 5:31 PM

$JAGX Any potential buyers please look at the institutional holdings and ask yourself, if the leadership doen not beleeive in the company enough to own shares why should you?

0 · Reply

Omago78 Apr. 10 at 5:29 PM

$JAGX She has been floating that same garbage line since she bankrupted Shaman with these drugs... how do you promote this company with any kind of concience ?

0 · Reply

andycoolbeans Apr. 10 at 5:23 PM

$JAGX as she said this morning B is for billions as in the potential market for antidiarrheal medicines .Cancer therapy-related diarrhea (CTD/CID): ~$80–89 million across 7 major markets (US + EU4 + UK + Japan) recently, with the US alone at ~$40 million. Projected growth to ~$165 million by 2035. The company has always struggled with lining everything up. Poorly managed no one disputes that.

0 · Reply

MarketManStockWizzard Apr. 10 at 5:06 PM

$JAGX to be clear, the company is bankrupt if the note is called.

0 · Reply

MarketManStockWizzard Apr. 10 at 4:52 PM

$JAGX if streetervilles note wasnt deferred, we would be -$10.8m market cap.

0 · Reply

MarketManStockWizzard Apr. 10 at 4:50 PM

$JAGX these sell offs always amaze me. Why it dosent freefall to single digits right now is amazing.

0 · Reply

MarketManStockWizzard Apr. 10 at 3:55 PM

$JAGX so, what did she say? Any good questions? Any good answers?

0 · Reply

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Apr 8, 2026, 8:30 AM EDT - 2 days ago

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Apr 7, 2026, 8:30 AM EDT - 3 days ago

Jaguar Health Reports 2025 Financials

Apr 2, 2026, 9:00 AM EDT - 8 days ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Mar 18, 2026, 9:00 AM EDT - 23 days ago

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

Mar 16, 2026, 9:00 AM EDT - 25 days ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Mar 11, 2026, 9:00 AM EDT - 4 weeks ago

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Mar 9, 2026, 9:00 AM EDT - 4 weeks ago

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Mar 3, 2026, 9:00 AM EST - 5 weeks ago

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

Mar 2, 2026, 9:00 AM EST - 5 weeks ago

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Feb 18, 2026, 9:00 AM EST - 7 weeks ago

Jaguar Health Announces a Special One-time Stock Dividend

Jan 22, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jan 14, 2026, 9:00 AM EST - 3 months ago

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jan 12, 2026, 9:00 AM EST - 3 months ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Jan 6, 2026, 9:00 AM EST - 3 months ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jan 2, 2026, 9:00 AM EST - 3 months ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 15, 2025, 9:00 AM EST - 4 months ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Dec 10, 2025, 9:00 AM EST - 4 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 8, 2025, 4:15 PM EST - 4 months ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Dec 2, 2025, 9:00 AM EST - 4 months ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Nov 24, 2025, 9:00 AM EST - 4 months ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

Nov 20, 2025, 9:00 AM EST - 5 months ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Nov 17, 2025, 8:00 AM EST - 5 months ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Nov 14, 2025, 9:00 AM EST - 5 months ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Nov 13, 2025, 9:00 AM EST - 5 months ago

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

Nov 6, 2025, 9:00 AM EST - 5 months ago

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Oct 24, 2025, 4:15 PM EDT - 5 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 9:00 AM EDT - 6 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Sep 30, 2025, 9:00 AM EDT - 6 months ago

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Sep 25, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Sep 24, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Sep 23, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Sep 5, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Aug 21, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Aug 19, 2025, 4:15 PM EDT - 8 months ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Aug 19, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Aug 14, 2025, 8:00 AM EDT - 8 months ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Aug 12, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Jul 10, 2025, 8:30 AM EDT - 9 months ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jul 8, 2025, 9:00 AM EDT - 9 months ago

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Jun 30, 2025, 9:00 AM EDT - 10 months ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jun 26, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jun 25, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jun 24, 2025, 4:15 PM EDT - 10 months ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jun 23, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jun 17, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Jun 11, 2025, 10:00 AM EDT - 10 months ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jun 9, 2025, 4:15 PM EDT - 10 months ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 9, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jun 6, 2025, 9:00 AM EDT - 11 months ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

focafoca99 Apr. 10 at 6:07 PM

$JAGX will host an investor webcast https://www.rapidticker.com/news/jagx-reminder-jaguar-health-to-host-fe5ece

0 · Reply

Bunster Apr. 10 at 5:52 PM

$JAGX tell that to the 4 clueless pumpers

0 · Reply

andycoolbeans Apr. 10 at 5:48 PM

$JAGX billion dollar potential market ? "I am not uncertain“

1 · Reply

Omago78 Apr. 10 at 5:31 PM

$JAGX Any potential buyers please look at the institutional holdings and ask yourself, if the leadership doen not beleeive in the company enough to own shares why should you?

0 · Reply

Omago78 Apr. 10 at 5:29 PM

$JAGX She has been floating that same garbage line since she bankrupted Shaman with these drugs... how do you promote this company with any kind of concience ?

0 · Reply

andycoolbeans Apr. 10 at 5:23 PM

0 · Reply

MarketManStockWizzard Apr. 10 at 5:06 PM

$JAGX to be clear, the company is bankrupt if the note is called.

0 · Reply

MarketManStockWizzard Apr. 10 at 4:52 PM

$JAGX if streetervilles note wasnt deferred, we would be -$10.8m market cap.

0 · Reply

MarketManStockWizzard Apr. 10 at 4:50 PM

$JAGX these sell offs always amaze me. Why it dosent freefall to single digits right now is amazing.

0 · Reply

MarketManStockWizzard Apr. 10 at 3:55 PM

$JAGX so, what did she say? Any good questions? Any good answers?

0 · Reply

Omago78 Apr. 10 at 3:08 PM

$JAGX The only thing dying here is your networth lol...

0 · Reply

czarfast1 Apr. 10 at 1:23 PM

$JAGX How can we do that? Do you have Jaguar shares? I thought you were here to piss people off?

1 · Reply

MarketManStockWizzard Apr. 10 at 1:13 PM

$JAGX r&d cost of $4M dont go away. How do we plan to cover this xpense? No more mytesi or canalevia?

0 · Reply

Bunster Apr. 10 at 1:10 PM

$JAGX if the nasdaq issues ruling fast we could be delisted within days.oh today is friday. u know bad SEC filings are dropped ah on fridays. HOW WILL OUR 4 BULLS SPIN DELISTING IF WE GET DELISTED?. DONT WORRY GIRLS , THEY WILL . NASDAQ RULING IS ALL THAT MATTERS.AND THEN THE MEETING IN A MATTER OF DAYS AND THE REVERSE SPLIT VOTE AND THE MASSIVE DILUTION. LETS NOT TALK ABOUT THAT.

0 · Reply

andycoolbeans Apr. 10 at 1:06 PM

$JAGX Oh I, I just died in your arms tonight It must have been something you said

0 · Reply

MarketManStockWizzard Apr. 10 at 1:03 PM

$JAGX still broke... still going to dilute. Still going to reverse split. Thank you Management

0 · Reply

Bunster Apr. 10 at 1:02 PM

$JAGX

0 · Reply

schrisrice Apr. 10 at 10:53 AM

$JAGX Picture is worth a thousand words. This tells you what you need to know about investing your $ in JAG.

0 · Reply

Oruveek70 Apr. 10 at 9:15 AM

$JAGX 'financials and company updates' lol. 'The (tried and trusted) "modus operandi" in April 2026 is focused on surviving immediate Nasdaq delisting notices while restructuring debt to delay cash outlays.' Not that CEO Lisa Conte, and other board members like Peter Hodge need to lose too much sleep over their 'fiduciary responsibility' as they have been well rewarded by failure over time imo. Whose looking forward to the 'investor' webcast? https://www.newswire.com/news/reminder-jaguar-health-to-host-investor-webcast-at-8-30-am-eastern-on-friday

0 · Reply

MarketManStockWizzard Apr. 10 at 8:21 AM

$JAGX what Bunster is saying is true. We need to attribute 1st q losses as well. That brings us well below $0.00 which is obviously below the $2.5m required to remain compliant. However, here we are.

0 · Reply

Bunster Apr. 10 at 1:48 AM

$JAGX swim at your own risk when u see other posters here post math or numbers , unless it comes from prime . .

0 · Reply

Bunster Apr. 10 at 1:28 AM

$JAGX SO BECAUSE THE FIRST TIME NASDAQ WAS AWARE OF OUR STOCKHOLDERS DEF NOT BEING IN COMPLIANCE was on april 7 . as of march 31 2026.The last numbers nasdaq got from us was sept 30 2025 when the stockholders def was not an issue. i hope i educated the bulls and bears on here. prime

0 · Reply

Market Cap	1.53M
Revenue (ttm)	11.69M
Net Income (ttm)	-38.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-329.26%
Debt to Equity Ratio	1.75

Volume	333,317
Avg Vol	487,328
Day's Range	N/A - N/A
Shares Out	3.74M
Stochastic %K	52%
Beta	0.27
Analysts	Strong Buy
Price Target	$16.00